Clinical specificity profile for novel rapid acting antidepressant drugs
Open Access
- 30 June 2023
- journal article
- review article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 38 (5) , 297-328
Abstract
Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric acid, orexin, and other receptors, providing a broader range of pharmacodynamic mechanisms, that is, expected to increase the possibility of personalizing treatments on the individual clinical profile. These new drugs were developed with the aim of combining a rapid action, a tolerable profile, and higher effectiveness on specific symptoms, which were relatively poorly targeted by standard antidepressants, such as anhedonia and response to reward, suicidal ideation/behaviours, insomnia, cognitive deficits, and irritability. This review discusses the clinical specificity profile of new antidepressants, namely 4-chlorokynurenine (AV-101), dextromethorphan-bupropion, pregn-4-en-20-yn-3-one (PH-10), pimavanserin, PRAX-114, psilocybin, esmethadone (REL-1017/dextromethadone), seltorexant (JNJ-42847922/MIN-202), and zuranolone (SAGE-217). The main aim is to provide an overview of the efficacy/tolerability of these compounds in patients with mood disorders having different symptom/comorbidity patterns, to help clinicians in the optimization of the risk/benefit ratio when prescribing these drugs.Keywords
This publication has 117 references indexed in Scilit:
- Prediction of Psilocybin Response in Healthy VolunteersPLOS ONE, 2012
- GABAergic neuroactive steroids: a new frontier in bipolar disorders?Behavioral and Brain Functions, 2012
- Orexin, stress, and anxiety/panic states2012
- Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant MedicationJournal of Clinical Psychopharmacology, 2011
- Psychomotor retardation in depression: Biological underpinnings, measurement, and treatmentProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- The GABAergic deficit hypothesis of major depressive disorderMolecular Psychiatry, 2010
- Ketamine and the next generation of antidepressants with a rapid onset of actionPharmacology & Therapeutics, 2009
- Postpartum DepressionAJN, American Journal of Nursing, 2006
- The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cordNeuroscience Letters, 1997
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979